Abstract
The discovery of the von Hippel-Lindau (VHL) gene marked a milestone in our understanding of clear cell renal cell carcinoma (ccRCC) pathogenesis. VHL inactivation is not only a defining feature of ccRCC, but also the initiating event. Herein, we discuss canonical and noncanonical pVHL functions, as well as breakthroughs shaping our understanding of ccRCC evolution and evolutionary subtypes. We conclude by presenting evolving strategies to therapeutically exploit effector mechanisms downstream of pVHL.
Original language | English (US) |
---|---|
Pages (from-to) | 390-398 |
Number of pages | 9 |
Journal | Cancer Journal (United States) |
Volume | 26 |
Issue number | 5 |
DOIs | |
State | Published - Sep 1 2020 |
Externally published | Yes |
Keywords
- AROHIF2
- MK-6482
- PT2385
- PT2977
- hypoxia-inducible factor
- siRNA
- synthetic lethality
- tumor evolution
ASJC Scopus subject areas
- Oncology
- Cancer Research